Keybank National Association OH Decreases Stock Position in argenex SE $ARGX

Keybank National Association OH decreased its stake in shares of argenex SE (NASDAQ:ARGX) by 29.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,336 shares of the company’s stock after selling 564 shares during the period. Keybank National Association OH’s holdings in argenex were worth $976,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ARGX. Oppenheimer & Co. Inc. increased its stake in shares of argenex by 2.8% during the fourth quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock valued at $372,000 after acquiring an additional 12 shares during the period. Valeo Financial Advisors LLC increased its position in shares of argenex by 0.9% during the 4th quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock valued at $1,153,000 after purchasing an additional 12 shares during the period. CI Investments Inc. raised its stake in shares of argenex by 2.6% in the 4th quarter. CI Investments Inc. now owns 469 shares of the company’s stock worth $394,000 after buying an additional 12 shares in the last quarter. Allworth Financial LP lifted its holdings in shares of argenex by 12.7% in the fourth quarter. Allworth Financial LP now owns 115 shares of the company’s stock valued at $97,000 after buying an additional 13 shares during the period. Finally, Raiffeisen Bank International AG lifted its holdings in shares of argenex by 12.6% in the fourth quarter. Raiffeisen Bank International AG now owns 134 shares of the company’s stock valued at $112,000 after buying an additional 15 shares during the period. 60.32% of the stock is currently owned by institutional investors.

argenex Stock Up 0.3%

Shares of NASDAQ ARGX opened at $919.94 on Wednesday. argenex SE has a 12-month low of $536.02 and a 12-month high of $953.58. The firm’s 50-day simple moving average is $846.35 and its 200 day simple moving average is $811.75. The company has a market cap of $57.21 billion, a price-to-earnings ratio of 40.96, a price-to-earnings-growth ratio of 1.13 and a beta of 0.45.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. The firm had revenue of $1.31 billion during the quarter. On average, equities analysts expect that argenex SE will post 26.27 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Wedbush reaffirmed an “outperform” rating and set a $1,000.00 target price on shares of argenex in a report on Thursday, June 11th. Bank of America raised their price objective on shares of argenex from $1,016.00 to $1,088.00 and gave the company a “buy” rating in a research report on Thursday, July 2nd. Deutsche Bank Aktiengesellschaft upgraded shares of argenex from a “hold” rating to a “buy” rating in a report on Tuesday, March 10th. HC Wainwright reaffirmed a “buy” rating and issued a $940.00 price target on shares of argenex in a report on Thursday, June 25th. Finally, Glj Research upgraded argenex to a “strong-buy” rating in a research report on Friday, April 3rd. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,037.61.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.